Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 09:01 am Purchase |
2024-12-31 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 9,256,953 15.000% |
829,998 (+9.85%) |
Filing History |
| 2024-12-26 4:31 pm Sale |
2024-12-20 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 7,404,869 12.000% |
-629,131 (-7.83%) |
Filing History |
| 2024-11-14 5:21 pm Sale |
2024-03-31 | 13G | Passage Bio, Inc. PASG |
Erste Asset Management GmbH | 2,455,800 4.420% |
-505,000 (-17.06%) |
Filing History |
| 2024-11-14 5:01 pm Purchase |
2023-12-31 | 13G | Passage Bio, Inc. PASG |
Erste Asset Management GmbH | 2,960,800 5.400% |
2,960,800 (New Position) |
Filing History |
| 2024-11-14 12:03 pm Purchase |
2024-09-30 | 13G | Passage Bio, Inc. PASG |
Vestal Point Capital, LP | 6,100,000 9.900% |
6,100,000 (New Position) |
Filing History |
| 2024-08-09 7:06 pm Sale |
2024-08-07 | 13D | Passage Bio, Inc. PASG |
Versant Venture Capital VI, L.P. | 0 0.000% |
-4,026,417 (Position Closed) |
Filing History |
| 2024-08-09 5:15 pm Purchase |
2024-08-07 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 8,426,955 13.600% |
3,581,084 (+73.90%) |
Filing History |
| 2024-05-29 4:35 pm Unchanged |
2024-05-24 | 13D | Passage Bio, Inc. PASG |
Versant Venture Capital VI, L.P. | 4,026,417 6.500% |
0 (Unchanged) |
Filing History |
| 2024-04-12 5:35 pm Unchanged |
2024-04-09 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 8,034,000 13.000% |
0 (Unchanged) |
Filing History |
| 2024-03-29 4:15 pm Purchase |
2024-03-19 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 4,845,871 8.700% |
4,466,712 (+1178.06%) |
Filing History |
| 2024-02-14 09:21 am Sale |
2023-12-31 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 379,159 0.700% |
-2,976,758 (-88.70%) |
Filing History |
| 2023-11-09 5:27 pm Unchanged |
2023-08-07 | 13D | Passage Bio, Inc. PASG |
Versant Venture Capital VI, L.P. | 4,026,417 7.300% |
0 (Unchanged) |
Filing History |
| 2023-06-29 4:36 pm Purchase |
2023-06-27 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 8,034,000 14.700% |
1,192,577 (+17.43%) |
Filing History |
| 2023-06-15 10:25 am Sale |
2023-06-13 | 13D | Passage Bio, Inc. PASG |
Frazier Life Sciences IX L.P. | 2,543,698 4.700% |
-1,213,217 (-32.29%) |
Filing History |
| 2023-02-14 4:06 pm Purchase |
2022-12-31 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 3,355,917 6.200% |
603,495 (+21.93%) |
Filing History |
| 2023-02-14 08:53 am Sale |
2022-12-31 | 13G | Passage Bio, Inc. PASG |
Deep Track Capital, LP | 0 0.000% |
-3,216,997 (Position Closed) |
Filing History |
| 2022-09-29 4:30 pm Purchase |
2022-09-19 | 13G | Passage Bio, Inc. PASG |
Lynx1 Capital Management LP | 2,752,422 5.100% |
2,752,422 (New Position) |
Filing History |
| 2022-08-15 11:29 am Sale |
2022-08-11 | 13D | Passage Bio, Inc. PASG |
Frazier Life Sciences IX L.P. | 3,756,915 6.900% |
-1,264,523 (-25.18%) |
Filing History |
| 2022-07-08 4:56 pm Sale |
2022-06-30 | 13G | Passage Bio, Inc. PASG |
BLACKROCK INC BLK |
1,368,347 2.500% |
-2,123,208 (-60.81%) |
Filing History |
| 2022-05-05 4:56 pm Purchase |
2022-05-03 | 13D | Passage Bio, Inc. PASG |
ORBIMED ADVISORS LLC | 6,841,423 12.600% |
894,100 (+15.03%) |
Filing History |